XTAE
ERKA
Market cap5mUSD
Oct 12, Last price
16.80ILS
Name
Erika B-Cure Laser Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Erika B-Cure Laser Ltd, established in Haifa, Israel in 2007, is a company dedicated to the full lifecycle of its B-Cure laser product line, from development and manufacturing to global marketing, sales, and distribution. Formerly known as Erica Carmel Ltd until its rebranding in January 2022, the company offers a diverse array of laser devices tailored for various therapeutic applications in both domestic and international markets. Their product portfolio includes: The B-Cure Laser Classic, a medical device for home use that addresses a broad spectrum of conditions including general pain, orthopedic issues, dermatological problems, inflammation, and supports wound healing. The B-Cure Laser Pro, designed to treat more severe or chronic ailments such as persistent orthopedic challenges, diabetic wounds, and difficulties in recovery, including mucositis. The B-Cure Laser Sport, a home-based device for managing sports injuries, athletic discomfort, and other orthopedic concerns. The professional-grade B-Cure Laser Sport Pro, which provides advanced treatment for sports-related injuries, pain relief in muscles and various body areas, and helps combat infections like Achilles tendonitis. For dental professionals, the B-Cure Laser Dental is an in-clinic device formulated to tackle a variety of oral health problems, alleviate gum pain and inflammation, expedite recovery post-dental procedures (including implants), and reduce associated swelling and discomfort. Additionally, the B-Pro Dental Laser Cure is available for dental clinics, specifically engineered to address diverse dental issues and infections.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||